Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

@article{Zhou2019AnlotinibVS,
  title={Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.},
  author={A. Zhou and Y. Bai and Y. Song and Hong Luo and X. Ren and X. Wang and B. Shi and C. Fu and Y. Cheng and Ji-Yan Liu and S. Qin and J. Li and H. Li and Xianzhong Bai and D. Ye and Jinwan Wang and J. Ma},
  journal={The oncologist},
  year={2019}
}
BACKGROUND Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first-line treatment for patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS Patients with mRCC from 13 clinical centers were randomly assigned in a 2:1 ratio to receive anlotinib (n = 90) or sunitinib (n = 43). Anlotinib was given orally at a dose of 12 mg once… Expand
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)
  • Yongkun Sun, A. Zhou, +8 authors Kan Liu
  • Medicine
  • Hepatology International
  • 2021
Anlotinib as a molecular targeted therapy for tumors.
...
1
2
3
...

References

SHOWING 1-10 OF 25 REFERENCES
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
  • T. Choueiri, S. Halabi, +10 authors M. Morris
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
  • Y. Sun, F. Du, +9 authors P. Tang
  • Medicine
  • Thyroid : official journal of the American Thyroid Association
  • 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma
...
1
2
3
...